SEC Tracker
Get the app

Rigel Pharmaceuticals RIGL

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Reports quarterly results (2.02)
  • Takes on a new financial obligation (2.03)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Rigel Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amarin AMRN public float $335M, Jun 30, 2025
  2. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  3. Altimmune ALT public float $327M, Jun 30, 2025
  4. Prothena Corp Public PRTA public float $327M, Jun 30, 2025
  5. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025